 |
|
| Access educational resources for your patients to help them better understand and manage their CML. Learn more > |
| Since its development, Glivec® has been a cornerstone of therapy for CML patients. Learn more > |
Welcome to CMLAlliance.net |
Welcome to CMLAlliance.net, a CML resource from Novartis Oncology for healthcare professionals. Building on more than 5 years of worldwide experience in improving outcomes in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), Novartis Oncology introduces a new support program—CML Alliance. CML Alliance offers a wealth of resources designed to help you and your patients optimize outcomes in Ph+ CML. Access monitoring, educational, clinical trial information, and more. When patients have Ph+ CML, you want to provide access to the full potential of advanced care for Ph+ CML . . . and now you can with CML Alliance. |
|
See European Summary of Product Characteristics Glivec 100 mg film coated tablets (PDF) Glivec 400 mg film coated tablets (PDF) Glivec 50 mg capsules, hard (PDF) Glivec 100 mg capsules, hard (PDF)
About CML Alliance | Treating CML | Targeted Therapies and CML Contact | Site Map | Privacy © 2008 Novartis AG |